NR1D1 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-21 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
The lowering of the blood cholesterol level can reduce the risk of coronary heart disease." β-glucan lowers cholesterol in part by increasing the viscosity of digesta in the small intestine, although cholesterol reduction is greater in those with higher total cholesterol and LDL cholesterol in their blood. Additionally, studies suggest that it increases the activity of CYP7A1, a key enzyme in the synthesis of bile acids, thus increasing the excretion of cholesterol, and that it may have additional anti-atherogenic mechanisms. The degree of cholesterol reduction depends upon the particular strain of β-glucan in a range between a molecular weights of 26.8 and 3000 kD. Although more viscous β-glucans result in a more viscous solution of intestinal digesta, and thus more cholesterol uptake, after a certain molecular weight, β-glucans become less soluble and thus contribute less to solution viscosity. The intake of β-glucan in liquid form generally results in greater solubilization and oat β-glucan is more effective at lowering cholesterol in juices than in hard foods like bread and cookies. Despite the recognized impact of viscosity on serum cholesterol levels, no current data exists comparing internal solution viscosity and serum cholesterol. Intake of oat β-glucan at daily amounts of at least 3 grams lowers total and low-density lipoprotein cholesterol levels by 5–10% in people with normal or elevated blood cholesterol levels.
== Service == It has eight strategic business units: Industrial Packaging, Greases & Lubricants, Chemicals, Travel & Vacations, Logistics Infrastructure, Logistics Services, Cold Chain and Refinery & Oil Field Services, with offices spread across the country and abroad. BL is present in eight businesses: Travel and Vacations, Industrial Packaging, Greases and Lubricants, Leather Chemicals, Logistics, Logistics Infrastructure, Logistics Services, and Refinery and Oil Field.
=== Regulation === Aside from deactivating radicals and reactive oxidants, glutathione participates in thiol protection and redox regulation of cellular thiol proteins under oxidative stress by protein S-glutathionylation, a redox-regulated post-translational thiol modification. The general reaction involves formation of an unsymmetrical disulfide from the protectable protein (RSH) and GSH:
Sources: en.wikipedia.org
== Side effects == Chlorprothixene has a strong sedative activity with a high incidence of anticholinergic side effects. The types of side effects encountered (dry mouth, massive hypotension and tachycardia, hyperhidrosis, substantial weight gain etc.) normally do not allow a full effective dose for the remission of psychotic disorders to be given. So cotreatment with another, more potent, antipsychotic agent is needed. Chlorprothixene is structurally related to chlorpromazine, with which it shares, in principle, all side effects. Allergic side effects and liver damage seem to appear with an appreciable lower frequency. The elderly are particularly sensitive to anticholinergic side effects of chlorprothixene (precipitation of narrow angle glaucoma, severe obstipation, difficulties in urinating, confusional and delirant states). In patients >60 years the doses should be particularly low. Early and late extrapyramidal side effects may occur but have been noted with a low frequency (one study with a great number of participants has delivered a total number of only 1%).
Research shows that children who participate in Head Start are more likely to eat better than children who don't participate in this program. Solutions to worldwide obesity problems require unique approaches that include lifestyle changes, health policies, advancements of healthcare, involvement of parents and concerned citizens and education to prevent this problem from escalating. Several school districts have banned sodas, junk foods and candy from vending machines and cafeterias. Programs have been formed to help improve this health crisis such as, Lets Move, Eat Smart, Move More, Weigh Less, and Weight Watchers are just a few that have helped people lose weight. Some towns have initiatives that are safe routes for children to walk or ride their bikes. This program is called "Safe Routes to School". Educational programs such as Head Start have been created to offer federal funded school meals to children. This was one way of teaching children about healthy choices and good nutrition. Also, to help reduce obesity, the federal and local governments in the United States have asked food and beverage industries to label all foods and drinks. These labels help consumers be more conscious about the foods and drinks they are buying. Make America Healthy Again is a campaign led by Robert F. Kennedy Jr. during The Second Trump administration. MAHA became a commitment to Donald Trump's 2024 Presidential campaign after Robert F. Kennedy Jr. suspended his campaign. Trump established The MAHA commission on February 13, 2025 to study and recommend policies on the U.S.
=== Moving-belt interface === The moving-belt interface (MBI) was developed by McFadden et al. in 1977 and commercialized by Finnigan. This interface consisted of an endless moving belt onto which the LC column effluent was deposited in a band. On the belt, the solvent was evaporated by gently heating and efficiently exhausting the solvent vapours under reduced pressure in two vacuum chambers. After the liquid phase was removed, the belt passed over a heater which flash desorbed the analytes into the MS ion source. One of the significant advantages of the MBI was its compatibility with a wide range of chromatographic conditions. MBI was successfully used for LC–MS applications between 1978 and 1990 because it allowed coupling of LC to MS devices using EI, CI, and fast-atom bombardment (FAB) ion sources. The most common MS systems connected by MBI interfaces to LC columns were magnetic sector and quadrupole instruments. MBI interfaces for LC–MS allowed MS to be widely applied in the analysis of drugs, pesticides, steroids, alkaloids, and polycyclic aromatic hydrocarbons. This interface is no longer used because of its mechanical complexity and the difficulties associated with belt renewal (or cleaning) as well as its inability to handle very labile biomolecules.
=== The Banana gang === In 2015, the Belgian authorities dismantled the Belgian-Moroccan Banana gang (Dutch: De Bananenbende), which was led by Karim A., Nabil A. and Khalid O.H., after a seizure that contained 3.4 tonnes of cocaine in Antwerp. The drugs were hidden in two containers of bananas from Colombia that had passed through Ecuador. The drugs were estimated of being worth near €100 million. The investigators admitted that the clan had been importing shipments of this type for many years and that they had important links with several Moroccan clans in the Netherlands. Fourteen people were arrested, including the manager of a hookah bar in Antwerp, and the owner of a car dealership. The Belgian intelligence services estimated that this clan generated around €300 million a year, with importing no more than 10 tonnes of cocaine from South America.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.